argus

SOLARA ACTIVE PHARMA SCIENCES LIMITED

NSE: SOLARAINE624Z010163,071 Cr

Timeline

Time (IST)TypeMEventSrc
15 May, 01:22 pmSolara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Strong Q4 26 Results and a solid finish to the fiscal Year".nse
15 May, 01:20 pmSolara Active Pharma Sciences Ltd - 541540 - Financial Results For The Quarter And Year Ended March 31, 2026bse
15 May, 01:16 pmSolara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the year ended March 31, 2026 and unaudited Financial Results for the quarter ended March 31, 2026, along with the Auditor's report for the said period.nse
11 May, 04:33 pmSolara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, May 15, 2026, at 15.00 (IST), to discuss the Company's audited financial results for the quarter and year ended March 31, 2026nse
08 May, 09:06 pmSolara Active Pharma Sciences Ltd - 541540 - Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 ('Listing Regulations')bse
28 Apr, 05:25 pmSolara Active Pharma Sciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.nse
28 Apr, 05:03 pmSolara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
28 Apr, 05:01 pmSolara Active Pharma Sciences Limited has informed the Exchange regarding the press release dated April 28, 2026, titled Solara is pleased to announce the successful closure of US FDA inspection of its Puducherry Facility with continued state of cGMP compliance.nse
07 Apr, 07:45 pmSOLARA: Solara Active Pharma Sciences Limited has informed the Exchange regarding the completion of dispatch of Second and Final call Money notice to the eligible Partly paid Rights equity shareholders.nse
30 Mar, 08:05 pmMembers of the Exchange are hereby informed that the trading in the partly paid-up equity shares (Series: E1, ISIN: IN9624Z01022) of Solara Active Pharma Sciences Limited shall be suspended w.e.f. April 02, 2026 (i.e., closing hours of trading on April 01, 2026) on account of second & final call.nse
24 Mar, 10:37 amSolara Active Pharma Sciences Limited has informed the Exchange that the Rights issue committee members at its meeting held on March 24, 2026, has approved the making of Second & Final call of Rs. 112.50/- per equity shares (Rs. 3.00/- towards face value and Rs.109.50/- towards securities premium) per Rights Share in respect of partly paid Rights Shares and Fixed the Record date as April 02, 2026 for the same.nse
24 Mar, 10:25 amSolara Active Pharma Sciences Limited has fixed April 02, 2026 as the Record date for the purpose of making Second and Final call for the shares issued on the Rights basis.nse
24 Mar, 10:20 amSolara Active Pharma Sciences Ltd - 541540 - Board Meeting Outcome for Outcome Of The Rights Issue Committee Meetingbse
24 Mar, 10:19 amSolara Active Pharma Sciences Limited has informed the Exchange that the Rights issue committee members at its meeting held on March 24, 2026, has approved the making of Second & Final call of ₹ 112.50/- per equity shares (₹ 3.00/- towards face value and ₹ 109.50/- towards securities premium) per Rights Share in respect of partly paid Rights Shares and Fixed the Record date as April 02, 2026 for the same.nse
19 Mar, 05:46 pmSolara Active Pharma Sciences Ltd - 541540 - Board Meeting Intimation for Prior Intimation Of Meeting Of Rights Issue Committeebse
18 Mar, 07:02 pmSolara Active Pharma Sciences Limited has informed the Exchange about the receipt of Demand Notice from the Income Tax Authorities.nse
18 Mar, 07:00 pmSolara Active Pharma Sciences Ltd - 541540 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015bse
04 Mar, 06:52 pmSolara Active Pharma Sciences Limited has informed the Exchange regarding Receipt of call money pursuant to the Second Reminder Notice issued for payment of First Call Money.nse
04 Mar, 05:01 pmSOLARA: Intimation regarding the closure of wholly owned subsidiary of the Company in Brazil.nse
10 Feb, 05:52 pmSolara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.nse
10 Feb, 05:48 pmSolara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
07 Feb, 04:33 pmNewspaper publication on February 07, 2026, with respect to the unaudited financial results for the quarter and nine months ended December 31, 2025nse
06 Feb, 06:51 pmSolara Active Pharma Sciences Limited has intimated the Exchange about the Audio Recording of the Q3 FY26 Earnings Call held on February 06, 2026.nse
06 Feb, 06:47 pmSolara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
06 Feb, 06:35 pmMonitoring Agency Report for the quarter ended December 31, 2025nse
06 Feb, 06:33 pmSolara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Monitoring Agency Reportbse
06 Feb, 03:54 pmSolara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication with respect to Second reminder for payment of the First Call money - Rights Issue (Partly paid- up shares)nse
06 Feb, 02:38 pmSolara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32nse
06 Feb, 02:36 pmSolara Active Pharma Sciences Ltd - 541540 - Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended December 31, 2025.bse
06 Feb, 02:24 pmSolara Active Pharma Sciences Ltd - 541540 - Announcement Under Regulation 30 Of SEBI (LODR), 2015 Regarding The Revision And Adoption Of Policies.bse
06 Feb, 02:19 pmThe Company has reviewed and approved the revised Policy for Determining Materiality of Events / Information for Disclosure to Stock Exchanges and Policy for Governance of Related Party Transactions.nse
06 Feb, 02:09 pmSolara Active Pharma Sciences Limited has informed the exchange regarding the press release dated February 06, 2026, titled "Solara Q3'26 Performance."nse
06 Feb, 02:07 pmSolara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Feb, 01:47 pmSolara Active Pharma Sciences Ltd - 541540 - Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended December 31, 2025bse
06 Feb, 01:47 pmSolara Active Pharma Sciences Limited has informed the exchange regarding inter alia, the unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025 along with the Limited Review Report for the said period.nse
04 Feb, 11:06 pmSolara Active Pharma Sciences Limited has informed the Exchange about dispatch of second reminder Notice for payment of first call under Rights Issue.nse
03 Feb, 03:03 pmSolara Active Pharma Sciences Limited has informed the Exchange about the revised Intimation of Schedule of Analyst / Institutional Investor call under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, to be held on Friday, February 06, 2026 at 3:30 P.M. to discuss the Company's unaudited financial results for the quarter ended December 31, 2025nse
30 Jan, 08:31 pmSolara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, February 06, 2026 to discuss the Company's unaudited financial results for the quarter ended December 31, 2025nse
30 Jan, 07:33 pmSolara Active Pharma Sciences Ltd - 541540 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended December 31, 2025.bse
17 Dec, 11:14 amSolara Active Pharma Sciences Limited has informed the Exchange about Reconstitution of Management Committeense
17 Dec, 11:01 amSolara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Change in Directoratebse
17 Dec, 11:00 amSolara Active Pharma Sciences Limited has informed the Exchange regarding Change in Director(s) of the company.nse
17 Dec, 10:52 amSolara Active Pharma Sciences Limited has informed the Exchange regarding Board Meeting held on December 17, 2025 interalia to consider appointment of Mr. Mohanraj (DIN:08420411) as Additional Executive Director and Whole Time Directornse
05 Dec, 06:21 pmSolara Active Pharma Sciences Limited has informed the Exchange regarding Resignation of Mr. Mohan Muthunarayanan as Whole Time Director & Chief Operating Officer of the company w.e.f. December 31, 2025.nse
05 Dec, 06:14 pmSolara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Resignation of Directorbse
04 Dec, 01:50 pmSolara Active Pharma Sciences Ltd - 541540 - Clarification On Volume Movementbse
04 Dec, 12:53 pmSolara Active Pharma Sciences Ltd - 541540 - Clarification sought from Solara Active Pharma Sciences Ltdbse
04 Dec, 09:59 amSignificant increase in volume has been observed in Solara Active Pharma Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Solara Active Pharma Sciences Limited has submitted their response.nse
03 Dec, 06:00 pmSignificant increase in volume has been observed in Solara Active Pharma Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.nse
19 Nov, 10:26 amSolara Active Pharma Sciences Limited has informed the Exchange regarding a press release titled "Solara is pleased to announce the successful closure of US FDA inspection of its Mangalore Facility with continued state of compliance on cGMP".nse